Top entities: Tingjun Yang, Ascentage Pharma, The Medicine Maker, United States — Food and Drug Administration, European Union — European Medicines Agency.

What category does this event fall under?

Business — classified as award recognition.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 26, 2026. Coverage continues to evolve.

Business award recognition

Dajun Yang named to Power List

Q: When did this event occur?

First reported Jul 26, 2026; last updated Jul 26, 2026.

Q: What is the market impact?

General. This recognition is unlikely to have a significant direct impact on Ascentage Pharma's stock price.

Analysis based on 6 articles · First reported Jul 26, 2026 · Last updated Jul 26, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

This recognition is unlikely to have a significant direct impact on Ascentage Pharma's stock price. However, it may enhance the company's reputation and visibility in the pharmaceutical industry, potentially supporting long-term investor confidence.

biotechnology pharmaceutical

Event Summary

Ascentage Pharma Group International announced that its Chairman and CEO, Dr. Tingjun Yang, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The Power List recognizes global leaders in drug discovery, manufacturing innovation, and patient access. Dr. Yang co-founded Ascentage Pharma in 2009 and has led the company to commercialize two innovative therapies, olverembatinib and lisaftoclax, in China. The company is advancing multiple global Phase III trials cleared by the U.S. FDA and EMA. This recognition highlights Dr. Yang's leadership in small molecule oncology drug development.

Key Actions

20 Tingjun Yang named to Power List

Entities Involved

per

Tingjun Yang

Dr. Tingjun Yang was named to The Medicine Maker Power List 2026, ranking No. 3 in Small Molecules, recognizing his leadership in oncology drug development.

Importance 100.0 Sentiment 15.0

stock

Ascentage Pharma

Ascentage Pharma's CEO received industry recognition, which may boost the company's profile and investor sentiment.

Importance 80.0 Sentiment 10.0

priv

The Medicine Maker

The Medicine Maker published its Power List 2026, featuring Dr. Yang as a top leader in small molecules.

Importance 20.0 Sentiment 0.0

govactor

United States — Food and Drug Administration

The FDA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the FDA.

Importance 10.0 Sentiment 0.0

govactor

European Union — European Medicines Agency

The EMA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the EMA.

Importance 10.0 Sentiment 0.0

cnt

China

Ascentage Pharma operates in China and has approvals from Chinese regulators, but this event does not directly impact the country.

Importance 5.0 Sentiment 0.0

cnt

United States

Ascentage Pharma has a U.S. presence and FDA clearances, but this event does not directly impact the country.

Importance 5.0 Sentiment 0.0

govactor

China — National Medical Products Administration

The NMPA approved lisaftoclax in 2025, but this event does not directly involve the NMPA.

Importance 5.0 Sentiment 0.0

exch

Ghana Stock Exchange

Ascentage Pharma is listed on HKEX, but this event does not directly impact the exchange.

Importance 5.0 Sentiment 0.0

exch

Nasdaq

Ascentage Pharma is listed on Nasdaq, but this event does not directly impact the exchange.

Importance 5.0 Sentiment 0.0

stock

Takeda Pharmaceutical Company

Takeda is a partner of Ascentage Pharma, but this event does not directly involve Takeda.